Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Proceeds From Insurance Settlement Operating Activities

Proceeds From Insurance Settlement Operating Activities at other companies

ADMA Biologics logo
ADMA BiologicsADMA
$400K—
CBL & Associates Properties logo
CBL & Associates PropertiesCBL
$244K—
Universal Technical Institute logo
Universal Technical InstituteUTI
$169K+383%
The Ensign Group logo
The Ensign GroupENSG
-$1.92M-356%
Kimco Realty logo
Kimco RealtyKIM
$869K+94.8%
Vistra logo
VistraVST
$186M—

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S4×-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromInsuranceSettlementOperatingActivities.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's proceeds from insurance settlement operating activities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's proceeds from insurance settlement operating activities?
ADMA Biologics (ADMA) reported proceeds from insurance settlement operating activities of $400K in Q1 2025.
What does proceeds from insurance settlement operating activities mean?
Cash inflows resulting from insurance claims related to normal business operations. These proceeds are typically non-recurring and provide insight into the company's recovery from operational disruptions or legal events.